| Drug Name |
Avapritinib |
| Drug ID |
BADD_D02531 |
| Description |
Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors.[A189339,L11136] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib].
Avapritinib was granted FDA approval on 9 January 2020.[L11136] |
| Indications and Usage |
Avapritinib is indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors with a platelet-derived growth factor receptor alpha exon 18 mutation.[A189339,L11136] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EX18 |
| DrugBank ID |
DB15233
|
| KEGG ID |
D11279
|
| MeSH ID |
C000707147
|
| PubChem ID |
118023034
|
| TTD Drug ID |
D0UO2P
|
| NDC Product Code |
11014-0404; 63285-869; 72064-150; 11014-0405; 72064-125; 11014-0403; 72064-120; 72064-130; 72064-110; 63285-868 |
| UNII |
513P80B4YJ
|
| Synonyms |
avapritinib | BLU-285 | ayvakit | (1S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo(2,1-f)(1,2,4)triazin-4-yl)-1-piperazinyl)-5-pyrimidinyl)ethanamine | 5-Pyrimidinemethanamine, alpha-(4-fluorophenyl)-alpha-methyl-2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo(2,1-f)(1,2,4)triazin-4-yl)-1-piperazinyl)-, (alphaS)- |
